Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 186

1.

The ubiquitin peptidase UCHL1 induces G0/G1 cell cycle arrest and apoptosis through stabilizing p53 and is frequently silenced in breast cancer.

Xiang T, Li L, Yin X, Yuan C, Tan C, Su X, Xiong L, Putti TC, Oberst M, Kelly K, Ren G, Tao Q.

PLoS One. 2012;7(1):e29783. doi: 10.1371/journal.pone.0029783. Epub 2012 Jan 18.

2.

Epigenetic identification of ubiquitin carboxyl-terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors.

Yu J, Tao Q, Cheung KF, Jin H, Poon FF, Wang X, Li H, Cheng YY, Röcken C, Ebert MP, Chan AT, Sung JJ.

Hepatology. 2008 Aug;48(2):508-18. doi: 10.1002/hep.22343.

PMID:
18666234
3.

Frequent CpG methylation of ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) in sporadic and hereditary Tunisian breast cancer patients: clinical significance.

Trifa F, Karray-Chouayekh S, Jmaa ZB, Jmal E, Khabir A, Sellami-Boudawara T, Frikha M, Daoud J, Mokdad-Gargouri R.

Med Oncol. 2013 Mar;30(1):418. doi: 10.1007/s12032-012-0418-2. Epub 2013 Jan 13.

PMID:
23315218
4.

The tumor suppressor UCHL1 forms a complex with p53/MDM2/ARF to promote p53 signaling and is frequently silenced in nasopharyngeal carcinoma.

Li L, Tao Q, Jin H, van Hasselt A, Poon FF, Wang X, Zeng MS, Jia WH, Zeng YX, Chan AT, Cao Y.

Clin Cancer Res. 2010 Jun 1;16(11):2949-58. doi: 10.1158/1078-0432.CCR-09-3178. Epub 2010 Apr 15.

5.

Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation.

Ummanni R, Jost E, Braig M, Lohmann F, Mundt F, Barett C, Schlomm T, Sauter G, Senff T, Bokemeyer C, Sültmann H, Meyer-Schwesinger C, Brümmendorf TH, Balabanov S.

Mol Cancer. 2011 Oct 14;10:129. doi: 10.1186/1476-4598-10-129.

6.

Cancer detection by ubiquitin carboxyl-terminal esterase L1 methylation in pancreatobiliary fluids.

Kato N, Yamamoto H, Adachi Y, Ohashi H, Taniguchi H, Suzuki H, Nakazawa M, Kaneto H, Sasaki S, Imai K, Shinomura Y.

World J Gastroenterol. 2013 Mar 21;19(11):1718-27. doi: 10.3748/wjg.v19.i11.1718.

7.

Genomic screening for genes upregulated by demethylation revealed novel targets of epigenetic silencing in breast cancer.

Fujikane T, Nishikawa N, Toyota M, Suzuki H, Nojima M, Maruyama R, Ashida M, Ohe-Toyota M, Kai M, Nishidate T, Sasaki Y, Ohmura T, Hirata K, Tokino T.

Breast Cancer Res Treat. 2010 Aug;122(3):699-710. doi: 10.1007/s10549-009-0600-1. Epub 2009 Oct 27.

PMID:
19859801
8.

CpG methylation of ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) and P53 mutation pattern in sporadic colorectal cancer.

Abdelmaksoud-Dammak R, Saadallah-Kallel A, Miladi-Abdennadher I, Ayedi L, Khabir A, Sallemi-Boudawara T, Frikha M, Daoud J, Mokdad-Gargouri R.

Tumour Biol. 2016 Feb;37(2):1707-14. doi: 10.1007/s13277-015-3902-4. Epub 2015 Aug 28.

PMID:
26314856
9.

[The role of hypermethylation in promoter region of ubiquitin carboxyl-terminal hydrolase L1 in human esophageal cancer].

Yan WJ, Guo MZ, Yang YS.

Zhonghua Nei Ke Za Zhi. 2012 May;51(5):390-3. Chinese.

PMID:
22883340
10.

Silencing of the UCHL1 gene in giant cell tumors of bone.

Fellenberg J, Lehner B, Witte D.

Int J Cancer. 2010 Oct 15;127(8):1804-12. doi: 10.1002/ijc.25205.

11.

Zinc-finger protein 545 inhibits cell proliferation as a tumor suppressor through inducing apoptosis and is disrupted by promoter methylation in breast cancer.

Xiao Y, Xiang T, Luo X, Li C, Li Q, Peng W, Li L, Li S, Wang Z, Tang L, Ren G, Tao Q.

PLoS One. 2014 Oct 31;9(10):e110990. doi: 10.1371/journal.pone.0110990. eCollection 2014.

12.

Epigenetic silencing of Aristaless-like homeobox-4, a potential tumor suppressor gene associated with lung cancer.

Liu WB, Han F, Du XH, Jiang X, Li YH, Liu Y, Chen HQ, Ao L, Cui ZH, Cao J, Liu JY.

Int J Cancer. 2014 Mar 15;134(6):1311-22. doi: 10.1002/ijc.28472. Epub 2013 Nov 11.

13.

Epigenetic control of the ubiquitin carboxyl terminal hydrolase 1 in renal cell carcinoma.

Seliger B, Handke D, Schabel E, Bukur J, Lichtenfels R, Dammann R.

J Transl Med. 2009 Oct 26;7:90. doi: 10.1186/1479-5876-7-90.

14.

Identification of methylation-silenced genes in colorectal cancer cell lines: genomic screening using oligonucleotide arrays.

Fukutomi S, Seki N, Koda K, Miyazaki M.

Scand J Gastroenterol. 2007 Dec;42(12):1486-94.

PMID:
17994469
15.

DACT1, an antagonist to Wnt/β-catenin signaling, suppresses tumor cell growth and is frequently silenced in breast cancer.

Yin X, Xiang T, Li L, Su X, Shu X, Luo X, Huang J, Yuan Y, Peng W, Oberst M, Kelly K, Ren G, Tao Q.

Breast Cancer Res. 2013 Mar 12;15(2):R23. doi: 10.1186/bcr3399.

16.

Epigenetic inactivation of paired box gene 5, a novel tumor suppressor gene, through direct upregulation of p53 is associated with prognosis in gastric cancer patients.

Li X, Cheung KF, Ma X, Tian L, Zhao J, Go MY, Shen B, Cheng AS, Ying J, Tao Q, Sung JJ, Kung HF, Yu J.

Oncogene. 2012 Jul 19;31(29):3419-30. doi: 10.1038/onc.2011.511. Epub 2011 Nov 21. Erratum in: Oncogene. 2012 Jul 19;31(29):3482.

PMID:
22105368
17.

Epigenetic silencing of the WNT antagonist Dickkopf 3 disrupts normal Wnt/β-catenin signalling and apoptosis regulation in breast cancer cells.

Xiang T, Li L, Yin X, Zhong L, Peng W, Qiu Z, Ren G, Tao Q.

J Cell Mol Med. 2013 Oct;17(10):1236-46. doi: 10.1111/jcmm.12099. Epub 2013 Jul 24.

18.

CpG hypermethylation of the UCHL1 gene promoter is associated with pathogenesis and poor prognosis in renal cell carcinoma.

Kagara I, Enokida H, Kawakami K, Matsuda R, Toki K, Nishimura H, Chiyomaru T, Tatarano S, Itesako T, Kawamoto K, Nishiyama K, Seki N, Nakagawa M.

J Urol. 2008 Jul;180(1):343-51. doi: 10.1016/j.juro.2008.02.044. Epub 2008 May 21.

PMID:
18499164
19.
20.

Frequent epigenetic inactivation of hSRBC in gastric cancer and its implication in attenuated p53 response to stresses.

Lee JH, Byun DS, Lee MG, Ryu BK, Kang MJ, Chae KS, Lee KY, Kim HJ, Park H, Chi SG.

Int J Cancer. 2008 Apr 1;122(7):1573-84.

Supplemental Content

Support Center